Envista Holdings Corp (NVST) - Forward Price-to-Revenue Multiple

envistaco.com (NVST) - corporate logo

Envista Holdings (NVST) dominates the dentistry market through its digital ecosystem and complex product certification. The forward P/S trend on the GURU.Markets chart, where 3.20 shows the current metric value, illustrates the valuation dynamics. The company minimizes risks via a broad range of implants and X-ray equipment, capitalizing on essential needs. However, inflation limits pricing power, forcing the implementation of discounts.

NVST envistaco.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/17/2026

Envista - analytical breakdowns and key metrics (NVST)

- market price and analyst price targets:
- market capitalization indicators:
General company analysis:NVST (Nobel Biocare)
Original product of envistaco.com

The selection of defensive assets is based on a combination of resilient operating models and environmental responsibility, as evidenced by Envista Holdings (NVST) transitioning to biodegradable packaging and eliminating mercury. An analysis of the company's forward P/S allows for a comparison of current market capitalization against expected revenue, determining the premium paid for future growth and filtering out market noise through the dynamics of the sales multiple.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio Baxter International Inc. (BAX)|MASI (masimo.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group Corp STVN|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Merit Medical - Market Cap to Projected Revenue|ICU Medical, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio XRAY (Dentsply Sirona Inc)|LMAT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio AtriCure Corp ATRC|staar.com (STAA) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple ChromaDex Corporation|ZIMV (ZimVie Inc) - Forward P/S Multiple|Market Cap to Projected Revenue ANGO (AngioDynamics)|Price-to-Projected Revenue Ratio Cerus Corp (CERS)|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com